Thalys(603716) 证券时报网·2025-01-20 02:01Core Viewpoint - The U.S. Department of Commerce has implemented new export control regulations prohibiting the export of high-parameter flow cytometers and specific mass spectrometry equipment to China and other designated countries, prompting the Chinese biotechnology sector to seek alternative equipment and technology sources [1] Company Summary - Seer Medical's Innovation Acceleration Center (TIAC) is actively promoting independent innovation and industrial upgrading of cutting-edge medical devices [1] - The company is focusing on the localization of the revolutionary early diagnosis technology for sepsis, TriVerity™, including early multi-center clinical research and registration applications in China [1] - Seer Medical has established a joint venture, LeviTech (Shanghai) Life Sciences Co., Ltd., with U.S. company LevitasBio® in Shanghai [1] - The LeviCell® system has received high recognition from top research institutions and biotechnology companies in China, including Shanghai Institute of Immunology, Fudan University, University of Science and Technology of China, and Berry Genomics [1] - In 2024, the LeviCell® system will enter the preparation phase for medical device registration certification, along with the domestic development of its core consumable, the microfluidic chip, which has shown test results meeting experimental expectations [1]